Weight Loss Medications, Drugs & Pills (2026)

Every drug with a weight-loss approval in 2026, in every form it is sold. That means the GLP-1 receptor agonists licensed for chronic weight management (Wegovy, Zepbound, Foundayo, Saxenda), the diabetes GLP-1s that doctors prescribe off-label for weight (Ozempic, Mounjaro), the older pills that are not GLP-1s (Qsymia, Contrave, Xenical), and what is still in late-phase trials. Each one is checked against its source.

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

Price and states served both move. Read them off the seller's own site before you enroll.How our reviews work →

About this page

Nothing appears below without an FDA approval and a published label on DailyMed or Drugs@FDA. How it works, what it is licensed for, how it is taken, and the approval date are pulled from our primary-source-verified drug database — see each drug's linked guide for verbatim FDA-label quotes, clinical-trial citations, and the editorial verification log. We do not paraphrase indication language and we do not invent comparisons that the published evidence does not support.

Weight loss pills vs weight loss injections

Weight loss medications come in two administration formats: oral pills (taken by mouth) and subcutaneous injections (self-administered, typically once weekly). The choice between them depends on FDA-approved indication, tolerability of needles, dosing convenience, and insurance coverage.

Weight loss pills (oral)

FDA-approved oral weight-loss options as of 2026:

Foundayo (orforglipron) — GLP-1 RA, daily tablet, FDA-approved April 2026
Wegovy tablet (oral semaglutide) — GLP-1 RA, daily tablet up to 25 mg, FDA-approved for weight management
Rybelsus (oral semaglutide) — GLP-1 RA for type 2 diabetes (off-label for weight loss), daily tablet; being discontinued in the US and replaced by Ozempic tablets
Qsymia (phentermine + topiramate) — non-GLP-1, daily capsule, FDA-approved 2012
Contrave (naltrexone + bupropion) — non-GLP-1, twice-daily tablet, FDA-approved 2014
Xenical / alli (orlistat) — non-GLP-1, three times daily, FDA-approved 1999 (Rx) / 2007 (OTC alli)

Weight loss injections (subcutaneous)

FDA-approved injectable weight-loss options:

Wegovy (semaglutide 2.4 mg) — once weekly, FDA-approved June 2021
Zepbound (tirzepatide) — once weekly, FDA-approved November 2023
Saxenda (liraglutide 3 mg) — once daily, FDA-approved December 2014
Ozempic (semaglutide for T2D) — once weekly, off-label for weight loss
Mounjaro (tirzepatide for T2D) — once weekly, off-label for weight loss

For the drug class itself — what a GLP-1 receptor agonist is, what it does, every approval, and why one molecule carries two brand names — see our GLP-1 complete guide.

The GLP-1s licensed for weight itself

These are the drugs FDA-approved specifically for weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbid condition.

Wegovy

Semaglutide

Drug class: GLP-1 receptor agonist
Administration: Subcutaneous injection once weekly (single-dose pre-filled pen or syringe, or the 4-dose Wegovy FlexTouch pen for the 2.4 mg dose) or, since December 2025, an oral tablet taken once daily
Manufacturer: Novo Nordisk A/S
FDA indication: Chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity (trials enrolled at BMI ≥30, or ≥27 with a comorbidity); weight reduction in pediatric patients aged 12+; cardiovascular risk reduction in adults with obesity and established cardiovascular disease; noncirrhotic MASH with moderate-to-advanced liver fibrosis in adults (August 2025). The oral tablet form (December 2025) covers the cardiovascular risk reduction and adult weight reduction indications only.

FDA status: FDA-approved for chronic weight management in adults with obesity or overweight with comorbidity (June 2021); cardiovascular risk reduction in adults with established CVD (March 2024); weight reduction in pediatric patients aged 12+ (December 2022); noncirrhotic MASH with moderate-to-advanced liver fibrosis in adults (August 2025, accelerated approval); and an oral tablet form for cardiovascular risk reduction or weight reduction in adults (December 2025), alongside the original injection

Full Wegovy guide →

Zepbound

Tirzepatide

Drug class: GIP and GLP-1 receptor agonist (dual incretin)
Administration: Subcutaneous injection (single-dose pre-filled pen and vial)
Manufacturer: Eli Lilly and Company
FDA indication: Chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity (trials enrolled at BMI ≥30, or ≥27 with a comorbidity); obstructive sleep apnea in adults with obesity

FDA status: FDA-approved for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity (trials enrolled at BMI ≥30, or ≥27 with a comorbidity) (November 2023), and in adults with obesity, for moderate to severe obstructive sleep apnea (December 2024)

Full Zepbound guide →

Foundayo

Orforglipron

Drug class: GLP-1 receptor agonist (oral non-peptide small molecule)
Administration: Oral, once daily
Manufacturer: Eli Lilly and Company
FDA indication: Chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity

FDA status: FDA-approved for chronic weight management in adults with obesity, or overweight with weight-related medical problems, alongside a reduced-calorie diet and increased physical activity (April 1, 2026). Not approved for pediatric use. Cannot be used with other GLP-1 receptor agonists.

Full Foundayo guide →

Licensed for diabetes, prescribed off-label for weight

What the FDA approved these for is blood sugar in type 2 diabetes — not weight on its own. They get written off-label for weight anyway, usually when the properly indicated drug cannot be got hold of or will not be paid for. Prescribing off-label is both lawful and routine; getting an insurer to fund it that way rarely is.

Ozempic

Semaglutide

Drug class: GLP-1 receptor agonist
Administration: Subcutaneous injection once weekly (single-patient-use pen or single-dose prefilled syringe); Ozempic tablets by mouth once daily
Manufacturer: Novo Nordisk A/S
FDA indication: Injection: glycemic control in adults with type 2 diabetes mellitus; cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease; reduction of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Ozempic tablets: glycemic control in adults with type 2 diabetes; cardiovascular risk reduction in adults with type 2 diabetes at high risk of major cardiovascular events.

FDA status: Injection: FDA-approved for glycemic control in type 2 diabetes (December 2017), to reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease (2020), and to reduce kidney function decline, kidney failure and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (January 2025). Ozempic tablets, taken once daily and on sale since May 4, 2026, share Rybelsus's label: glycemic control in adults with type 2 diabetes and fewer major cardiovascular events in those at high risk. Weight loss is off-label use.

Full Ozempic guide →

Mounjaro

Tirzepatide

Drug class: GIP and GLP-1 receptor agonist (dual incretin)
Administration: Subcutaneous injection (single-dose pre-filled pen)
Manufacturer: Eli Lilly and Company
FDA indication: Glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes mellitus; reduction of major adverse cardiovascular events in adults with type 2 diabetes at high risk for these events (August 2026)

FDA status: FDA-approved for type 2 diabetes in adults (May 2022) and in children 10 and older (December 2025), and to reduce major cardiovascular events in adults with type 2 diabetes at high risk (August 2026). Off-label use for weight loss is common; the weight management indication is covered by Zepbound (FDA-approved November 2023).

Full Mounjaro guide →

Pipeline: drugs in late-stage clinical trials

Each of these has phase 2 or phase 3 data published and no FDA approval yet. NCT IDs, completion dates and checked topline results are laid out trial by trial in our GLP-1 Pipeline Tracker (2026). Quick summary below:

Retatrutide — Eli Lilly. Triple agonist (GLP-1 / GIP / glucagon). The strongest weight-loss readout in any GLP-1 trial to date. See our retatrutide evidence article.
CagriSema — Novo Nordisk. Cagrilintide (amylin analog) + semaglutide combination. See the CagriSema REDEFINE results.
MariTide (maridebart cafraglutide) — Amgen. GLP-1 / GIP receptor modulator with monthly dosing. See the GLP-1 pipeline article.
Survodutide — Boehringer Ingelheim & Zealand Pharma. GLP-1 / glucagon dual agonist. Coverage in the same pipeline article.
Ecnoglutide — from Sciwind. A long-acting GLP-1 agonist, still in late-stage trials. Covered in the pipeline article.

Other FDA-approved anti-obesity medications

The FDA has approved additional non-GLP-1 medications for chronic weight management — including Saxenda (liraglutide), Qsymia (phentermine + topiramate), Contrave (naltrexone + bupropion), Xenical / alli (orlistat), Plenity (cellulose hydrogel device), and Imcivree (setmelanotide for rare genetic obesity). We link to canonical FDA sources below while our verification queue advances.

Authoritative FDA-published landscape: NIDDK — Prescription Medications to Treat Overweight & Obesity. Drugs@FDA database for current label of any specific drug. We'll add dedicated guides for each of the older AOMs as our verification queue advances.

Patent cliff & generic timeline

Two FDA-approved generic GLP-1 receptor agonists already exist in the US: Hikma generic liraglutide referencing Victoza (December 2024) and Teva generic liraglutide 3 mg referencing Saxenda (August 2025). Wegovy, Ozempic, Rybelsus, Mounjaro, Zepbound, and Foundayo remain patent-protected; semaglutide composition-of-matter is widely modeled to expire in the early 2030s, and tirzepatide / orforglipron run later. Trulicity is on the BLA biosimilar pathway, not the generic pathway.

Which GLP-1 goes generic when — the patent cliff, drug by drug

Common questions about weight loss medications

Three carry a chronic-weight-management approval as of 2026: Wegovy, which is subcutaneous semaglutide from Novo Nordisk, approved June 2021; Zepbound, subcutaneous tirzepatide from Eli Lilly, November 2023; and Foundayo, oral orforglipron, also Lilly, on April 1, 2026. Saxenda — liraglutide, Novo Nordisk, December 2014 — holds an approval too, but it is written far less often now that semaglutide and tirzepatide have proved more effective.

No. The license covers blood-sugar control in type 2 diabetes, and stops there. The same molecules are sold for weight management under different names — semaglutide as Wegovy, tirzepatide as Zepbound. A prescriber may write Ozempic or Mounjaro off-label for weight, which is entirely legal, but an insurer will rarely pay for it on that basis.

Different molecules doing related things. Wegovy is semaglutide, acting on the GLP-1 receptor alone. Zepbound is tirzepatide, acting on GIP as well. On the trial numbers, SURMOUNT-1 put tirzepatide 15 mg at roughly 21% mean body-weight loss by week 72 (Jastreboff et al., NEJM 2022), against roughly 15% at 2.4 mg of semaglutide in STEP-1 (Wilding et al., NEJM 2021) — separate trials, so read that as a rough sense of scale rather than a head-to-head. Both are weekly subcutaneous injections, and their approved indications are near-identical: adults with obesity, or with overweight plus at least one weight-related illness. Their trials enrolled at a BMI of 30 or more, or 27 or more with such an illness.

The FDA approved orforglipron on April 1, 2026, as a long-term weight-management drug. No oral non-peptide agonist had ever got that far before. The semaglutide tablets (Rybelsus, which Ozempic tablets are replacing in the US, and the Wegovy tablet) are a modified peptide; this one is a small molecule, so none of their fasting protocol applies. One tablet daily. It is approved for adults only, and it cannot be taken alongside another GLP-1 receptor agonist.

For most of them, nobody can say yet. Foundayo (orforglipron), the drug the ATTAIN trials tested, was approved on April 1, 2026. As of October 30, 2026, CagriSema (Novo Nordisk) was under FDA review: Novo filed it in December 2025 and expects a US decision in the fourth quarter of 2026. Lilly plans to submit retatrutide, its triple agonist, in the first quarter of 2027, and results from TRIUMPH-1 and TRIUMPH-2 were published in September and October 2026. MariTide (Amgen), survodutide (Boehringer Ingelheim with Zealand Pharma) and ecnoglutide (Sciwind) were still in late-stage trials with no FDA approval. The pipeline section above links the published data.

Several, and they predate this whole class. Qsymia pairs phentermine with topiramate; Contrave pairs naltrexone with bupropion; Xenical and alli are orlistat; Plenity is a cellulose hydrogel; and Imcivree is setmelanotide, for rare genetic obesity. Most take off less weight than a GLP-1 does, which is why they now sit behind them — but they remain the answer for anyone who cannot tolerate a GLP-1 or cannot get hold of one. The NIDDK landscape overview linked above is the canonical FDA-sourced list.

Where to go next

Weight loss injections guide →

Every FDA-approved injectable option (Wegovy, Zepbound, Saxenda) plus off-label T2D injectables, the pipeline, cost, and the cross-trial caveats SURMOUNT-1 vs STEP-1 vs SCALE require.

State-by-state Medicaid coverage →

State by state, worked from the PDLs and provider notices themselves. Texas is the one to read first; California, New York and Florida are linked from inside it.

Best semaglutide providers →

Every telehealth seller of semaglutide, compounded or branded, ordered on price and on how openly it operates.

Best tirzepatide providers →

Every telehealth seller of tirzepatide, compounded or branded, ordered on price and on how openly it operates.

Live GLP-1 pricing index →

What the brand lists, what compounded costs in cash, and what a savings card does to either — across every channel we track.

Insurance coverage by insurer →

What Medicare, Medicaid and the large private plans (Aetna, Cigna, Humana, Kaiser, UnitedHealthcare and the Anthem BCBS plans) require before they pay, and what you are left owing.

Research library →

Our writing on side effects, interactions with other drugs, what happens over years, what surgeons need to know, and choosing between bariatric surgery and a GLP-1 — every claim traced to a source.